Economic assessment, a field between clinical research and observational studies;L'évaluation socio-économique, une discipline entre recherche clinique et études observationnelles

Bulletin du Cancer

Volumn 90, Issue 1, 2003, Pages 97-104

  Launois, Robert ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b REES France   (France)

Author keywords

Economic assessment; Markov model; Probabilistic sensitivity analysis; Study design

Indexed keywords

CLINICAL PRACTICE; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; PROBABILITY; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION SUPPORT TECHNIQUES; DECISION TREES; MARKOV CHAINS; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY;

EID: 17144440058     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Beck RJ, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 1983; 3: 419-58.
2. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical Decision Making 1993; 13: 322-38.
3. Launois R, Croutsche JJ, Mégnigbêto A, Le Lay K, Portafax C. L'apport indispensable de l'épidémiologie clinique aux modèles de Markov. Journal d'Economie Médicale 1999; 17: 343-61.
4. Launois R, Schulenburg M, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int J Psychiat Clin Pract 1998; 2 (Suppl 2), S79-S86.
5. Launois R, Mégnigbêto AC, Lelay K, Présenté G, Gitoud M, Durand I, et al. L'accident vasculaire cérébral en France: efficacité er coût des unités neuro-vasculaires par rapport aux soins conventionnels. A paraître.
6. Launois R, Reboul-Marty J, Bonneterre J. Evaluation médico-économique de la chimiothérapie de deuxième ligne clans le cancer du sein métastatique: comparaison du docétaxel, du paclitaxel et de la vinorelbine. Bull Cancer 1997; 84: 709-21.
7. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmaco Economies 1996; 10: 504-21.
8. Launois R. Approche socio-économique. Cancer colorectal métastatique: actualités et perspectives. Congrès de Monaco du 5 octobre 1996. Référence Oncologie Médicale 1997; 1: 12-4.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
10. Kleinbaum DG, Kupper LL, Mogenstern H. Principles and quantitative methods: epidemiologic research. London: Lifetime Learning Publications 1982, 529.
11. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Medical Decision Making 1994; 14: 52-8.
12. Beck JR, Pauker SG, Gottlieb JE. A convenient approximation of life expectancy (the « Deale »): II. Use in medical decision making. Am J Med 1982; 73: 889-97.
13. Le Chevalier T. Randomized study of vinorelbin and cisplatin vs vindesine and cisplatin vs vinorelbin alone in advanced non small cell lung cancer. J Clin Oncol 1994; 12: 360-7.
14. De Pierre. Vinorelbin vs vinorelbin plus cisplatin in advanced non small cell lung cancer. Ann Oncol 1994; 5: 37-42.
15. Launois R, Portafax C, Perrocheau G. Cancer du côlon - Chimiothérapie de seconde ligne: les enjeux. Le Moniteur Hospitalier 1999; 112: 18-24.
16. Launois R. Les études médico-économiques sur Internet: le cancer du côlon métastatique. Hospitalisation Nouvelle 2001; 284: 27-8.
17. Launois R, Portafax C, Le Lay K, Perrocheau G. Internet pharmacoeconomic studies in metastatic colotecral cancer. Crit Rev Oncol/Hematol 2001; 38: 63-77.
18. Launois R. Un coût, des coûts, quels coûts? Journal d'Economie Médicale 1999; 17: 77-82.
19. Detournay B, Planes A, Vochelle N, Fagnani F. Cost-effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998; 13 (Pt I): 81-9.
20. Lamure M, Dansette GY, Sapede C, Thuriez A, Jirou-Najou JL, Duru G. Evaluation économique du déremboursement d'un mucolytique: un modèle de simulation en situation pragmatique. Journal d'Economie Médicale 1995; 13: 153-69.
21. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3: 233-45.
22. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
23. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommandations of the panel on cost-effectiveness in health and medecine. JAMA 1996; 276: 1253-8.
24. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Ptobabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5: 157-77.
25. Launois R, Riou-França L, Guider B, Aergertet P, Huet X, Meshaka P, et al. Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients. Abstract ESICM Barcelona. Intensive Care Medicine 2002; 28 (supp. 1): n° 624 p. S161.
26. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, Effects and C/E ratios alongside a clinical trial. Health Economics 1994; 3: 309-19.
27. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996; 5: 297-305.
28. Heitjan DF, Moskowitz AJ, Whang W. Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making 1999; 19: 9-15.
29. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000; 17: 339-49.
30. Tengs TO, Adams ME, Pliskin JS, Gelb Safran D, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Society for Risk Analysis 1995; 369-90.